%0 Journal Article
%T Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease
%A Aaron Lucas
%A Ann Cameron
%A Michele Wilson
%A Michelle Luo
%J Archive of "American Health & Drug Benefits".
%D 2018
%X Vedolizumab is a biologic drug approved by the US Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) who have had inadequate response to, lost response to, or were intolerant of immunomodulators or tumor necrosis factor (TNF) blocker therapy, or who had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroid therapy. The biologics approved by the FDA for CD and/or UC include adalimumab, infliximab, golimumab, certolizumab, and ustekinumab
%K adalimumab
%K anti-TNF biologic drug
%K budget impact model
%K certolizumab
%K Crohn's disease
%K golimumab
%K health plan formulary
%K infliximab
%K ulcerative colitis
%K vedolizumab
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207303/